ArriVent BioPharma, Inc. Common Stock
AVBP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Assets | – | – | – | – |
| Cash & Equivalents | $113 | $113 | $50 | $74 |
| Short-Term Investments | $188 | $123 | $126 | $145 |
| Receivables | $1 | $1 | $1 | $1 |
| Inventory | $0 | $0 | $0 | $0 |
| Other Curr. Assets | $20 | $14 | $9 | $8 |
| Total Curr. Assets | $321 | $250 | $186 | $227 |
| Property Plant & Equip (Net) | $0 | $0 | $0 | $0 |
| Goodwill | $0 | $0 | $0 | $0 |
| Intangibles | $0 | $0 | $0 | $0 |
| Long-Term Investments | $5 | $19 | $29 | $48 |
| Tax Assets | $0 | $0 | $0 | $0 |
| Other NC Assets | $0 | $0 | $0 | $0 |
| Total NC Assets | $5 | $19 | $30 | $48 |
| Other Assets | $0 | $0 | $0 | $0 |
| Total Assets | $327 | $270 | $215 | $275 |
| Liabilities | – | – | – | – |
| Payables | $6 | $4 | $4 | $4 |
| Short-Term Debt | $0 | $0 | $0 | $0 |
| Tax Payable | $0 | $0 | $0 | $0 |
| Deferred Revenue | $0 | $0 | $0 | $0 |
| Other Curr. Liab. | $16 | $15 | $8 | $13 |
| Total Curr. Liab. | $22 | $20 | $13 | $17 |
| LT Debt | $0 | $0 | $0 | $0 |
| Deferred Rev, NC | $0 | $0 | $0 | $0 |
| Deferred Tax Liab, NC | $0 | $0 | $0 | $0 |
| Other NC Liab. | $0 | $0 | $0 | $0 |
| Total NC Liab. | $0 | $0 | $0 | $0 |
| Other Liabilities | $0 | $0 | $0 | $0 |
| Cap. Leases | $0 | $0 | $0 | $0 |
| Total Liabilities | $22 | $20 | $13 | $17 |
| Equity | – | – | – | – |
| Pref Stock | $0 | $0 | $0 | $0 |
| Common Stock | $0 | $0 | $0 | $0 |
| Retained Earnings | -$369 | -$334 | -$303 | -$238 |
| AOCI | $0 | -$0 | -$0 | -$0 |
| Other Equity | $674 | $584 | $505 | $496 |
| Total Equity | $305 | $250 | $203 | $258 |
| Supplemental Information | – | – | – | – |
| Minority Interest | $0 | $0 | $0 | $0 |
| Total Liab. & Tot. Equity | $327 | $270 | $215 | $275 |
| Net Debt | -$113 | -$113 | -$50 | -$74 |